Those feared of capital raising, along with stop losses, triggered today's sell-off. Unfortunately, I missed the opportunity at high 40s.
Cash as at 30 June 2024: $22m;
- R&D refund (usually receiving in October): should be around $10.9m (43.5% of the total R&D of $25.2m for the 2024 financial year);
- DXBO option exercising before 30 June 2025: $7.6m
Total available cash would be $40.5m
Total cash expenditures for last two financial years:
- 2023 financial year was $20m; and
- 2024 financial year was $28m.
Nina said the licensing deals (i.e US and China), will be signed before mid 2025.
The CR selloff is not justified, imo.
Ann: Quarterly Appendix 4C and Activities Report, page-58
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.8¢ |
Change
-0.003(0.66%) |
Mkt cap ! $211.7M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 38.5¢ | 37.3¢ | $347.5K | 918.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 184486 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 33634 | 8 |
View Market Depth
| Last trade - 14.38pm 03/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |